Nervgen Pharma Corp. company information, Employees & Contact Information

NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones Yahoo Finance

NervGen Pharma Reports Positive Topline Data from the GlobeNewswire

NervGen Pharma Grants Stock Options Newsfile

NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates Yahoo Finance

NervGen Announces Leadership Transition to Support Strategic Growth and Expansion Newsfile

Insights on NervGen Pharma’s Positive Phase 1b/2a Data for NVG-291 in Spinal Cord Injury NeurologyLive

NervGen Provides Quarterly "At-The-Market" Equity Program and Grant of Options Update Yahoo Finance

NervGen Pharma Reports Second Quarter Financial Results and Provides Letter to Shareholders Newsfile

NervGen Pharma: Risky, Yet Promising With Big Upside Seeking Alpha

NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting Yahoo Finance

NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury Newsfile

NervGen Initiates Expanded Access Policy Yahoo Finance

NervGen Pharma to Present at the Virtual Life Science Investor Forum Newsfile

NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth Yahoo Finance

NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates Yahoo Finance

NervGen Completes Dosing of First Subject in Subacute Cohort of its Phase 1b/2a Clinical Trial of NVG-291 in Spinal Cord Injury Yahoo Finance

NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role Yahoo Finance

NervGen Pharma Reports 2023 Year-End Financial Results and Operational Updates Yahoo Finance

NervGen Pharma Receives Fast Track Designation for NVG-291 for the Treatment of Individuals with Spinal Cord Injury Yahoo Finance

NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage Yahoo Finance

NervGen Pharma on Track to Complete Enrollment, Deliver Data Readout in Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Yahoo Finance

NervGen Pharma to Proceed with Landmark Phase 1b/2a Clinical Trial for NVG-291 in Spinal Cord Injury Having Completed FDA Review and Received IRB Approval Yahoo Finance

NervGen Pharma to Present on its Drug Candidate NVG-291 and Spinal Cord Injury at Investor Conference Yahoo Finance

NervGen Pharma Appoints Michael Kelly as President & Chief Executive Officer Yahoo Finance

NervGen Pharma Reports 2022 Year End Results and Provides Operational Update Including Plans to Initiate Phase 1b/2a Clinical Trial of Proprietary NVG-291 in Q3 2023 Yahoo Finance

NervGen Pharma’s NVG-291-R Demonstrates Significant Functional Repair From a Stroke 7 Days After Onset in Landmark Preclinical Study by University of Cincinnati and Case Western Reserve University Business Wire

NervGen: A High-Stakes Bet on a Groundbreaking Nerve Repair Drug NAI500

NervGen: Data For Spinal Cord Injury Treatment Candidate Likely For Mid-2025 Seeking Alpha

Q&A: Sustained functional recovery the goal for spinal cord injury treatment Healio

NervGen Pharma Reports Q1 2023 Results and Provides Operational Update Including Clinical Trials of Proprietary NVG-291 Newsfile

NervGen Pharma Closes US$15MM Private Placement and Appoints Dr. Adam Rogers to Board of Directors Newsfile

NervGen: Modulating Immune Cells For Spinal Cord Injury, Multiple Sclerosis And Alzheimer's Seeking Alpha

NervGen Pharma Presenting Phase 1b/2a Study Design at American Spinal Injury Association 50th Annual Scientific Meeting Newsfile

NervGen Pharma is a buy, Research Capital says Cantech Letter

How restoring brain plasticity is the key to reversing brain damage NR Times

Advancing Medical Innovations from Battlefield to Mainstream Medicine for Traumatic Brain Injury and Spinal Cord Injury Patients gritdaily.com

Road to Nervous System Repair Inspired by 20th Century Nobel Prize Winner Technology Networks

New Hope for Treating Neurodegenerative Diseases North American Precis Syndicate, Inc.

FOR YOUR HEALTH: Helping The Nervous System Heal Itself The Town Line Newspaper

NervGen has lots of upside from here, says iA Capital Cantech Letter

Biotechnology’s Role in Improving Stroke Outcomes Contract Pharma

Paradigm Capital doubles its price target on NervGen Pharma Cantech Letter

New Hope for People with Alzheimer’s Disease News-Herald